- Motley Fool•yesterday
Bristol-Myers Squibb and Gilead Sciences are strong buys after a poor 2016. But Dynavax is probably best avoided after its steep drop-off this year.
U.S. President-elect Donald Trump's plan to incentivize U.S. companies to repatriate their swelling overseas cash piles could spur a new wave of dealmaking in a pharmaceutical industry seeking to buy its ...
- Barrons.com•2 days ago
After Gilead Sciences (GILD) provided updates on its Bruton's tyrosine kinase, or BTK, and spleen tyrosine kinase, or Syk, hematology programs American Society of Hematology, Credit Suisse analyst Alethia ...
GILD : Summary for Gilead Sciences, Inc. - Yahoo Finance
Gilead Sciences Inc. (GILD)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||72.53 x 600|
|Ask||72.55 x 500|
|Day's Range||71.55 - 72.90|
|52 Week Range||71.39 - 104.79|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||6.71|
|Dividend & Yield||1.88 (2.60%)|
|1y Target Est||N/A|